We are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.
Our R&D focus is on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.
Belgium is home to three major vaccine research, development and manufacturing sites in Wavre, Rixensart and Gembloux. GSK is one of the world's leading vaccine manufacturers, with a portfolio of infant, adolescent and adult vaccines, as well as vaccines in development. In Belgium, the >8.5000 employees make it by far the largest pharmaceutical company.
With more than 66 years of presence in Türkiye, GSK has established a longterm and trusted role in Türkiye and continues to contribute to the healthcare ecosystem, with a particular focus on prevention through vaccination. GSK products positively impact over 30 million patients in Türkiye, with approximately one in every three people using a GSK medicine or vaccine.
